Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

NK cell expression of Tim-3: First impressions matter.

So EC, Khaladj-Ghom A, Ji Y, Amin J, Song Y, Burch E, Zhou H, Sun H, Chen S, Bentzen S, Hertzano R, Zhang X, Strome SE.

Immunobiology. 2019 May;224(3):362-370. doi: 10.1016/j.imbio.2019.03.001. Epub 2019 Mar 2.

2.

Intratumor genetic heterogeneity in squamous cell carcinoma of the oral cavity.

Zandberg DP, Tallon LJ, Nagaraj S, Sadzewicz LK, Zhang Y, Strome MB, Zhao XE, Vavikolanu K, Zhang X, Papadimitriou JC, Hubbard FA, Bentzen SM, Strome SE, Fraser CM.

Head Neck. 2019 Aug;41(8):2514-2524. doi: 10.1002/hed.25719. Epub 2019 Mar 14.

PMID:
30869813
3.

The evolving role of immuno-oncology for the treatment of head and neck cancer.

Strome AL, Zhang X, Strome SE.

Laryngoscope Investig Otolaryngol. 2019 Jan 10;4(1):62-69. doi: 10.1002/lio2.235. eCollection 2019 Feb. Review.

4.

A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity.

Zhang X, Owens J, Olsen HS, So E, Burch E, McCroskey MC, Li X, Weber GL, Bennett D, Rybin D, Zhou H, Hao H, Mérigeon EY, Block DS, LaRosa G, Strome SE.

JCI Insight. 2019 Jan 24;4(2). pii: 121905. doi: 10.1172/jci.insight.121905. [Epub ahead of print]

5.

Is routine genetic testing warranted in head and neck paragangliomas?

Gupta N, Strome SE, Hatten KM.

Laryngoscope. 2019 Jul;129(7):1491-1493. doi: 10.1002/lary.27656. Epub 2018 Dec 27. Review. No abstract available.

PMID:
30588632
6.

A fully recombinant human IgG1 Fc multimer (GL-2045) inhibits complement-mediated cytotoxicity and induces iC3b.

Zhou H, Olsen H, So E, Mérigeon E, Rybin D, Owens J, LaRosa G, Block DS, Strome SE, Zhang X.

Blood Adv. 2017 Mar 14;1(8):504-515. doi: 10.1182/bloodadvances.2016001917. eCollection 2017 Mar 14.

7.

Recombinant human IgG1 based Fc multimers, with limited FcR binding capacity, can effectively inhibit complement-mediated disease.

Sun H, Olsen HS, Mérigeon EY, So E, Burch E, Kinsey S, Papadimitriou JC, Drachenberg CB, Bentzen SM, Block DS, Strome SE, Zhang X.

J Autoimmun. 2017 Nov;84:97-108. doi: 10.1016/j.jaut.2017.08.004. Epub 2017 Aug 19.

PMID:
28830653
8.

What additional treatment is indicated for oral cavity cancer with isolated perineural invasion?

Hatten KM, Gupta N, Strome SE.

Laryngoscope. 2017 Sep;127(9):1965-1966. doi: 10.1002/lary.26577. Epub 2017 Mar 27. Review. No abstract available.

PMID:
28349551
9.

Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.

Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S.

Cancer. 2017 Apr 1;123(7):1259-1271. doi: 10.1002/cncr.30449. Epub 2016 Dec 1.

10.

The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment.

Pai SI, Zandberg DP, Strome SE.

Oral Oncol. 2016 Oct;61:152-8. doi: 10.1016/j.oraloncology.2016.08.001. Epub 2016 Aug 5. Review.

11.

Anti-CD20 Antibody with Multimerized Fc Domains: A Novel Strategy To Deplete B Cells and Augment Treatment of Autoimmune Disease.

Zhang X, Olsen HS, Chen S, So E, Zhou H, Burch E, Mérigeon EY, Block DS, Strome SE.

J Immunol. 2016 Feb 1;196(3):1165-76. doi: 10.4049/jimmunol.1501755. Epub 2015 Dec 22.

12.

RFX transcription factors are essential for hearing in mice.

Elkon R, Milon B, Morrison L, Shah M, Vijayakumar S, Racherla M, Leitch CC, Silipino L, Hadi S, Weiss-Gayet M, Barras E, Schmid CD, Ait-Lounis A, Barnes A, Song Y, Eisenman DJ, Eliyahu E, Frolenkov GI, Strome SE, Durand B, Zaghloul NA, Jones SM, Reith W, Hertzano R.

Nat Commun. 2015 Oct 15;6:8549. doi: 10.1038/ncomms9549.

13.

Impact of Detachment Methods on M2 Macrophage Phenotype and Function.

Chen S, So EC, Strome SE, Zhang X.

J Immunol Methods. 2015 Nov;426:56-61. doi: 10.1016/j.jim.2015.08.001. Epub 2015 Aug 5.

PMID:
26253940
14.

Invariant natural killer T cells generated from human adult hematopoietic stem-progenitor cells are poly-functional.

Sun W, Wang Y, East JE, Kimball AS, Tkaczuk K, Kesmodel S, Strome SE, Webb TJ.

Cytokine. 2015 Mar;72(1):48-57. doi: 10.1016/j.cyto.2014.12.009. Epub 2015 Jan 5.

15.

A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

Zandberg DP, Rollins S, Goloubeva O, Morales RE, Tan M, Taylor R, Wolf JS, Schumaker LM, Cullen KJ, Zimrin A, Ord R, Lubek JE, Suntharalingam M, Papadimitriou JC, Mann D, Strome SE, Edelman MJ.

Cancer Immunol Immunother. 2015 Mar;64(3):367-79. doi: 10.1007/s00262-014-1640-x. Epub 2014 Dec 24.

16.

Oropharyngeal cancer as a driver of racial outcome disparities in squamous cell carcinoma of the head and neck: 10-year experience at the University of Maryland Greenebaum Cancer Center.

Zandberg DP, Liu S, Goloubeva O, Ord R, Strome SE, Suntharalingam M, Taylor R, Morales RE, Wolf JS, Zimrin A, Lubek JE, Schumaker LM, Cullen KJ.

Head Neck. 2016 Apr;38(4):564-72. doi: 10.1002/hed.23933. Epub 2015 Jun 30.

17.

Fc fusion as a platform technology: potential for modulating immunogenicity.

Levin D, Golding B, Strome SE, Sauna ZE.

Trends Biotechnol. 2015 Jan;33(1):27-34. doi: 10.1016/j.tibtech.2014.11.001. Epub 2014 Dec 6. Review.

PMID:
25488117
18.

Immature teratoma of the maxillary sinus: a rare pediatric tumor.

Chang AE, Ambro BT, Strome SE, Papadimitriou JC, Pereira KD.

JAMA Otolaryngol Head Neck Surg. 2014 Sep;140(9):870-2. doi: 10.1001/jamaoto.2014.1800.

PMID:
25144659
19.

The anti-lymphoma activities of anti-CD137 monoclonal antibodies are enhanced in FcγRIII(-/-) mice.

Sallin MA, Zhang X, So EC, Burch E, Cai L, Lin W, Chapoval AI, Strome SE.

Cancer Immunol Immunother. 2014 Sep;63(9):947-58. doi: 10.1007/s00262-014-1567-2. Epub 2014 Jun 14.

PMID:
24927849
20.

The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck.

Zandberg DP, Strome SE.

Oral Oncol. 2014 Jul;50(7):627-32. doi: 10.1016/j.oraloncology.2014.04.003. Epub 2014 May 10. Review.

PMID:
24819861
21.

In response to What are the best management strategies for radiation-induced xerostomia?

Hutchinson CT, Strome SE, Suntharalingam M.

Laryngoscope. 2014 Sep;124(9):E397. doi: 10.1002/lary.24675. Epub 2014 Apr 29. No abstract available.

PMID:
24623594
22.

Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.

Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Xu YY, Kalos M, Cai L, Fang HB, Weiss BM, Badros A, Yanovich S, Akpek G, Tsao P, Cross A, Mann D, Philip S, Kerr N, Brennan A, Zheng Z, Ruehle K, Milliron T, Strome SE, Salazar AM, Levine BL, June CH.

Clin Cancer Res. 2014 Mar 1;20(5):1355-65. doi: 10.1158/1078-0432.CCR-13-2817. Epub 2014 Feb 11.

23.

What are the best management strategies for radiation-induced xerostomia?

Hutchinson CT, Suntharalingam M, Strome SE.

Laryngoscope. 2014 Feb;124(2):359-60. doi: 10.1002/lary.24035. Epub 2013 Sep 19. Review. No abstract available.

PMID:
24105656
24.

Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.

Jain A, Poonia B, So EC, Vyzasatya R, Burch EE, Olsen HS, Mérigeon EY, Block DS, Zhang X, Schulze DH, Hanna NN, Twadell WS, Yfantis HG, Chan SL, Cai L, Strome SE.

Eur J Cancer. 2013 Oct;49(15):3344-52. doi: 10.1016/j.ejca.2013.06.009. Epub 2013 Jul 18.

PMID:
23871153
25.

Surgical management of craniofacial neurofibromatosis type 1 associated tumors.

Janes LE, Sabino J, Matthews JA, Papadimitriou JC, Strome SE, Singh DP.

J Craniofac Surg. 2013 Jul;24(4):1273-7. doi: 10.1097/SCS.0b013e318285d337. Review.

PMID:
23851786
26.

CD40 mediates downregulation of CD32B on specific memory B cell populations in rheumatoid arthritis.

Zhang X, Burch E, Cai L, So E, Hubbard F, Matteson EL, Strome SE.

J Immunol. 2013 Jun 15;190(12):6015-22. doi: 10.4049/jimmunol.1203366. Epub 2013 May 17.

27.

A high throughput method for enrichment of natural killer cells and lymphocytes and assessment of in vitro cytotoxicity.

So EC, Sallin MA, Zhang X, Chan SL, Sahni L, Schulze DH, Davila E, Strome SE, Jain A.

J Immunol Methods. 2013 Aug 30;394(1-2):40-8. doi: 10.1016/j.jim.2013.05.001. Epub 2013 May 13.

PMID:
23680234
28.

Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma.

Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, Akpinarli A, Fulton A, Tamada K, Strome SE, Antony PA.

J Immunol. 2013 May 1;190(9):4899-909. doi: 10.4049/jimmunol.1300271. Epub 2013 Mar 27.

29.

What is the value of hyperbaric oxygen therapy in management of osteoradionecrosis of the head and neck?

Lubek JE, Hancock MK, Strome SE.

Laryngoscope. 2013 Mar;123(3):555-6. doi: 10.1002/lary.23496. No abstract available.

PMID:
23444188
30.

Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice.

Jain A, Olsen HS, Vyzasatya R, Burch E, Sakoda Y, Mérigeon EY, Cai L, Lu C, Tan M, Tamada K, Schulze D, Block DS, Strome SE.

Arthritis Res Ther. 2012 Aug 20;14(4):R192. doi: 10.1186/ar4024.

31.

Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma.

Voskens CJ, Sewell D, Hertzano R, DeSanto J, Rollins S, Lee M, Taylor R, Wolf J, Suntharalingam M, Gastman B, Papadimitriou JC, Lu C, Tan M, Morales R, Cullen K, Celis E, Mann D, Strome SE.

Head Neck. 2012 Dec;34(12):1734-46. doi: 10.1002/hed.22004. Epub 2012 Jan 27.

32.

Herpesvirus entry mediator regulates hypoxia-inducible factor-1α and erythropoiesis in mice.

Sakoda Y, Anand S, Zhao Y, Park JJ, Liu Y, Kuramasu A, van Rooijen N, Chen L, Strome SE, Hancock WW, Chen L, Tamada K.

J Clin Invest. 2011 Dec;121(12):4810-9. doi: 10.1172/JCI57332. Epub 2011 Nov 14.

33.

Cell type-specific transcriptome analysis reveals a major role for Zeb1 and miR-200b in mouse inner ear morphogenesis.

Hertzano R, Elkon R, Kurima K, Morrisson A, Chan SL, Sallin M, Biedlingmaier A, Darling DS, Griffith AJ, Eisenman DJ, Strome SE.

PLoS Genet. 2011 Sep;7(9):e1002309. doi: 10.1371/journal.pgen.1002309. Epub 2011 Sep 29.

34.

A noncoding point mutation of Zeb1 causes multiple developmental malformations and obesity in Twirler mice.

Kurima K, Hertzano R, Gavrilova O, Monahan K, Shpargel KB, Nadaraja G, Kawashima Y, Lee KY, Ito T, Higashi Y, Eisenman DJ, Strome SE, Griffith AJ.

PLoS Genet. 2011 Sep;7(9):e1002307. doi: 10.1371/journal.pgen.1002307. Epub 2011 Sep 29.

35.

Bone marrow vaccination: a novel approach to enhance antigen specific antitumor immunity.

Fresnay S, Zhang X, Strome SE, Sewell DA.

Vaccine. 2011 Nov 3;29(47):8599-605. doi: 10.1016/j.vaccine.2011.09.022. Epub 2011 Sep 25.

36.

Expression of anti-HVEM single-chain antibody on tumor cells induces tumor-specific immunity with long-term memory.

Park JJ, Anand S, Zhao Y, Matsumura Y, Sakoda Y, Kuramasu A, Strome SE, Chen L, Tamada K.

Cancer Immunol Immunother. 2012 Feb;61(2):203-214. doi: 10.1007/s00262-011-1101-8. Epub 2011 Aug 30.

37.

Interleukin-7 inhibits tumor-induced CD27-CD28- suppressor T cells: implications for cancer immunotherapy.

Zhang Y, Pfannenstiel LW, Bolesta E, Montes CL, Zhang X, Chapoval AI, Gartenhaus RB, Strome SE, Gastman BR.

Clin Cancer Res. 2011 Aug 1;17(15):4975-86. doi: 10.1158/1078-0432.CCR-10-3328. Epub 2011 Jun 28.

38.

Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010.

Ertl HC, Zaia J, Rosenberg SA, June CH, Dotti G, Kahn J, Cooper LJ, Corrigan-Curay J, Strome SE.

Cancer Res. 2011 May 1;71(9):3175-81. doi: 10.1158/0008-5472.CAN-10-4035. Erratum in: Cancer Res. 2011 Jun 15;71(12):4325.

39.

Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement.

Maniar A, Zhang X, Lin W, Gastman BR, Pauza CD, Strome SE, Chapoval AI.

Blood. 2010 Sep 9;116(10):1726-33. doi: 10.1182/blood-2009-07-234211. Epub 2010 Jun 2.

40.

B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance.

Park JJ, Omiya R, Matsumura Y, Sakoda Y, Kuramasu A, Augustine MM, Yao S, Tsushima F, Narazaki H, Anand S, Liu Y, Strome SE, Chen L, Tamada K.

Blood. 2010 Aug 26;116(8):1291-8. doi: 10.1182/blood-2010-01-265975. Epub 2010 May 14.

41.

CD44 is a marker for the outer pillar cells in the early postnatal mouse inner ear.

Hertzano R, Puligilla C, Chan SL, Timothy C, Depireux DA, Ahmed Z, Wolf J, Eisenman DJ, Friedman TB, Riazuddin S, Kelley MW, Strome SE.

J Assoc Res Otolaryngol. 2010 Sep;11(3):407-18. doi: 10.1007/s10162-010-0211-x. Epub 2010 Apr 13.

42.

CD137 promotes proliferation and survival of human B cells.

Zhang X, Voskens CJ, Sallin M, Maniar A, Montes CL, Zhang Y, Lin W, Li G, Burch E, Tan M, Hertzano R, Chapoval AI, Tamada K, Gastman BR, Schulze DH, Strome SE.

J Immunol. 2010 Jan 15;184(2):787-95. doi: 10.4049/jimmunol.0901619. Epub 2009 Dec 11.

43.

Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas.

Kottke T, Pulido J, Thompson J, Sanchez-Perez L, Chong H, Calderwood SK, Selby P, Harrington K, Strome SE, Melcher A, Vile RG.

Cancer Res. 2009 Oct 1;69(19):7767-74. doi: 10.1158/0008-5472.CAN-09-1597. Epub 2009 Sep 8.

44.

Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome.

Voskens CJ, Strome SE, Sewell DA.

Curr Mol Med. 2009 Aug;9(6):683-93. Review.

PMID:
19689295
45.

Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients.

Settle K, Posner MR, Schumaker LM, Tan M, Suntharalingam M, Goloubeva O, Strome SE, Haddad RI, Patel SS, Cambell EV 3rd, Sarlis N, Lorch J, Cullen KJ.

Cancer Prev Res (Phila). 2009 Sep;2(9):776-81. doi: 10.1158/1940-6207.CAPR-09-0149. Epub 2009 Jul 29.

46.

Identification of potential therapeutic targets in human head & neck squamous cell carcinoma.

Han J, Kioi M, Chu WS, Kasperbauer JL, Strome SE, Puri RK.

Head Neck Oncol. 2009 Jul 14;1:27. doi: 10.1186/1758-3284-1-27.

47.

Epitope mapping of a chimeric CD137 mAb: a necessary step for assessing the biologic relevance of non-human primate models.

Chan SL, Voskens CJ, Lin W, Schindler DG, Azimzadeh A, Wang LX, Taylor RJ, Strome SE, Schulze DH.

J Mol Recognit. 2009 May-Jun;22(3):242-9. doi: 10.1002/jmr.937.

PMID:
19177494
48.

FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck.

Taylor RJ, Chan SL, Wood A, Voskens CJ, Wolf JS, Lin W, Chapoval A, Schulze DH, Tian G, Strome SE.

Cancer Immunol Immunother. 2009 Jul;58(7):997-1006. doi: 10.1007/s00262-008-0613-3. Epub 2008 Nov 1. Erratum in: Cancer Immunol Immunother. 2009 Sep;58(9):1527-8.

PMID:
18979096
49.

Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma.

Alexander AA, Maniar A, Cummings JS, Hebbeler AM, Schulze DH, Gastman BR, Pauza CD, Strome SE, Chapoval AI.

Clin Cancer Res. 2008 Jul 1;14(13):4232-40. doi: 10.1158/1078-0432.CCR-07-4912.

50.

Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies.

Lin W, Voskens CJ, Zhang X, Schindler DG, Wood A, Burch E, Wei Y, Chen L, Tian G, Tamada K, Wang LX, Schulze DH, Mann D, Strome SE.

Blood. 2008 Aug 1;112(3):699-707. doi: 10.1182/blood-2007-11-122465. Epub 2008 Jun 2.

Supplemental Content

Loading ...
Support Center